X
GOSS icon

Xponance’s Gossamer Bio GOSS Stock Holding History

Xponance’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-215
Closed -$5.65K – 1854
2026
Q1 		$5.65K Buy
215
+29
+16% +$3.65K ﹤0.01% 1685
2025
Q4 		$46.2K Buy
186
+1
+0.5% +$228 ﹤0.01% 1529
2025
Q3 		$39K Buy
185
+2
+1% +$353 ﹤0.01% 1500
2025
Q2 		$18.1K Buy
+183
New +$16K ﹤0.01% 1499

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Xponance's GOSS Position: Q2 2026 in Review

Xponance sold out of Gossamer Bio (GOSS) in Q2 2026, closing a stake of 215 shares — an estimated $5.65K sold.

Xponance first reported a position in GOSS in Q2 2025 and held it in 4 quarters. The position peaked at $46.2K in Q4 2025. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Xponance reported no remaining Gossamer Bio position as of Q2 2026 after selling out during the quarter.
  • Xponance sold 215 Gossamer Bio shares in Q2 2026, an estimated $5.65K.
  • Xponance first reported a position in Gossamer Bio in Q2 2025 and held it in 4 quarters.
  • Xponance's Gossamer Bio position peaked at $46.2K in Q4 2025.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.